• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
Citation: LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
shu

Advances in BET bromodomain protein inhibitors

More Information
    Graphical Abstract
    • Abstract
  • Recognizing acetyl-lysine of histone is a key process of epigenetic regulation that is mediated by a protein module called bromodomain(BRD). The bromodomain inhibitors of the bromodomains and extra-terminal(BET)family have shown great potential in anti-inflammatory and antiproliferative effects. Through a review of diseases and structures about BET bromodomain, different kinds of inhibitors were analyzed and their structure-activity relationships were summarized. Herenin, the recent advances reported are reviewed for discovering more excellent small molecule inhibitors.
    • FullText(HTML)
    • References (52)
  • [1]
    Zhao S,Xu W,Jiang W,et al.Regulation of cellular metabolism by protein lysine acetylation[J].Science,2010,327(5968):1000-1004.
    [2]
    Tony K, Montellier E, Flint SJ, et al. Acetylation: a regulatory modification to rival phosphorylation[J]? EMBO J,2000,19(6):1176-1179.
    [3]
    Filippakopoulos P,Picaud S,Mangos M,et al.Histone recognition and large-scale structural analysis of the human bromodomain family[J].Cell,2012,149(1):214-231.
    [4]
    Shein NA,Shohami E.Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries[J].Mol Med,2011,13(3):29-39.
    [5]
    Gaucher J, Boussouar F, Montellier E, et al. Bromodomain-dependent stage-specific male genome programming by Brdt[J].EMBO J,2012,31(19):3809-3820.
    [6]
    LeRoy G,Rickards B,Flint SJ.The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription[J].Mol Cell,2008,30(1):51-60.
    [7]
    Denis GV,McComb ME,Faller DV,et al.Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines[J].J Proteome Res,2006,5(10):502-511.
    [8]
    Devaiah BN,Lewis BA,Cherman N,et al.BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain[J].Proc Natl Acad Sci U S A,2012,109(18):6927-6932.
    [9]
    Denis GV,Green MR.A novel,mitogen-activated nuclear kinase is related to a Drosophila developmental regulator[J].Genes Dev,1996, 10(3):261-271.
    [10]
    French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene:a novel mechanism in aggressive carcinoma[J].Cancer Res,2003, 63(2):304-307.
    [11]
    Delmore JE, Knapp S, Kouzarides T, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc[J].Cell,2011, 146(6):904-917.
    [12]
    Filippakopoulos P,Knapp S.The bromodomain interaction module[J].FEBS Lett,2012,586(17):2692-2704.
    [13]
    Haynes SR,Dollard C,Winston F,et al.The bromodomain:a conserved sequence found in human,Drosophila and yeast proteins [J].Nucleic Acids Res,1992,20(10):2603.
    [14]
    Rosner M,Hengstschlager M.Targeting epigenetic readers in cancer[J].N Engl J Med,2012,367(18):1764-1765.
    [15]
    Filippakopoulos P,Knapp S.The bromodomain interaction module[J].FEBS Lett,2012,586(17):2692-2704.
    [16]
    Winston F,Allis CD.The bromodomain:a chromatin-targeting module[J].Nat Struct Biol,1999,6(7):601-604.
    [17]
    Dawson MA,Kouzarides T,Huntly BJP.Targeting epigenetic readers in cancer[J].N Eng J Med,2012,367(7):647-657.
    [18]
    Mitsubishi Tanabe Pharma Corporation.Antitumor agent:WO,2009084693[P].2009-07-09[2015-01-14] .
    [19]
    Terri H,Finkel J,Wang GB.Compositions and methods for the treatment of HIV:US,20140199260[P].2014-07-17[2015-01-14] .
    [20]
    Dana-Farber Cancer Institute,Inc.Compositions and methods for treating neoplasia,inflammatory disease and other disorders:WO,2011143669[P].2011-11-17[2015-01-14] .
    [21]
    David S,Timothy PC,Laura E,et al.Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions[J].J Med Chem,2011,55(19):9393-9413.
    [22]
    Filippakopoulos P,Picaud S,Fedorov O,et al.Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family[J].Bioorg Med Chem,2012,20(6):1878-1886.
    [23]
    Yoshitomi Pharmaceutical Industries. Thienotriazolodiazepine compounds and medicinal uses thereof:WO,1998011111[P].1998-02-19[2015-01-14] .
    [24]
    Zhao Y,Yang CY,Wang S,et al.The making of I-BET762,a BET bromodomain inhibitor now in clinical development[J].J Med Chem,2013,56(19):7498-7500.
    [25]
    Rguet O,Gosmini R,Toum J,et al.Discovery of epigenetic regulator I-BET762:lead optimization to afford a clinical candidate inhibitor of the BET bromodomains[J].J Med Chem, 2013,56(19):7501-7515.
    [26]
    Bayer GMBH.BET-protein-inhibitors-5-aryl-triazolo-azepine:WO,2014048945[P].2014-04-03[2015-01-14] .
    [27]
    Constellation Pharmaceuticals,Inc.Bromodomain inhibitors and uses thereof:WO,2012151512[P].2012-11-08[2015-01-14] .
    [28]
    Constellation Pharmaceuticals,Inc.Bromodomain inhibitors and uses thereof:WO,2012174487[P].2012-12-10[2015-01-14] .
    [29]
    Boehringer Ingelheim GMBH.Triazolopyridazine:US,20140135336 [P].2014-10-07[2014-05-15] .
    [30]
    Fedorov O,Lingard H,Wells C,et al.[1,2,4] Triazolo[4,3-a ] phthalazines:inhibitors of diverse bromodomains[J].J Med Chem,2014,57(2):462-476.
    [31]
    Hewings DS,Wang M,Philpott M,et al.3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands[J].J Med Chem,2011,54(19):6761-6770.
    [32]
    Hewings DS,Fedorov O,Filippakopoulos P,et al.Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands[J].J Med Chem,2013,56(8):3217-3227.
    [33]
    Bamborough P,Diallo H,Goodacre JD,et al.Fragment-based discovery of bromodomain inhibitors part 2:optimization of phenylisoxazole sulfonamides[J].J Med Chem,2012,55(2):587-596.
    [34]
    Mirguet O,Lamotte Y,Donche F,et al.From ApoA1 upregulation to BET family bromodomain inhibition:discovery of I-BET151[J].Bioorg Med Chem Lett,2012,22(8):2963-2967.
    [35]
    Seal J,Lamotte Y,Donche F,et al.Identification of a novel series of BET family bromodomain inhibitors:binding mode and profile of I-BET151(GSK1210151A)[J].Bioorg Med Chem Lett,2012,22(8):2968-2972.
    [36]
    Glaxosmithkline LLC.Imidazo[4,5-C]quinoline derivates as bromodomain inhibitors:WO,2011054846[P].2011-05-12[2015-01-14] .
    [37]
    Duncan H,Oleg F,Panagis F,et al.The design and synthesis of 5-and 6-isoxazolyl benzimidazoles as selective inhibitors of the BET bromodomains[J].Med Chem Comm,2013,4(8):140-144.
    [38]
    Fedorov O,Martin S,Singleton DC,et al.Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains[J].J Am Chem Soc, 2013,10(37):1021-1034.
    [39]
    Constellation Pharmaceuticals,Inc.Bromodomain inhibitors and uses thereof:WO,2012075383[P].2012-06-07[2015-01-14] .
    [40]
    Victor SW,Michael CH,Rishi GV,et al.Discovery,design,and optimization of isoxazole azepine BET inhibitors[J].Med Chem Lett,2013,4(9):835-840.
    [41]
    Hewings DS,Wang M,Philpott M,et al.3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands[J].J Med Chem,2011,54(10),6761-6770.
    [42]
    Paul VF,Panagis F,Gerwyn B,et al.Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit[J].J Med Chem, 2012,55(22):9831-9837.
    [43]
    Picaud S,Da C,Thanasopoulou A,et al.PFI-1,a highly selective protein interaction inhibitor,targeting BET bromodomains[J].Cancer Res,2013,73(11):3336-3346.
    [44]
    Chung CW,Anthony WD,James M,et al.Fragment-based discovery of bromodomain inhibitors part 1:inhibitor binding modes and implications for lead discovery[J].J Med Chem,2012,55(2):576-586.
    [45]
    Glaxosmithkline LLC.Tetrahydroquinolines derivatives as bromodomain inhibitors:WO,2011054848[P].2011-05-12[2015-01-14] .
    [46]
    McLure KG,Gesner EM,Tsujikawa L,et al.RVX-208,an inducer of ApoA-I in humans,is a BET bromodomain antagonist[J].PLoS One,2013,8(12):3190-3201.
    [47]
    Resverlogix Corp.Compounds for the prevention and treatment of cardiovascular diseases:WO,2008092231[P].2008-08-07[2015-01-14] .
    [48]
    Nicholls SJ,Gordon A,Johansson J,et al.Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease:a randomized controlled trial[J].J Am Coll Cardiol,2011,57(23):1111-1119.
    [49]
    Bayer GMBH.BET-protein inhibitors dihydropyridopyrazinone:WO,2014095774[P].2014-06-26[2015-01-14] .
    [50]
    Zhao LL,Cao DY,Chen TT,et al.Fragment-based drug discovery of 2 thiazolidinones as inhibitors of the histone reader BRD4 bromodomain[J].J Med Chem, 2013,56(10):3833-3851
    [51]
    Abbvie,Inc.Bromodomain inhibitors:WO,2013097601[P].2013-07-04[2015-01-14] .
    [52]
    Lucas X,Wohlwend D,Hagle M,et al.4-Acyl pyrroles:mimicking acetylated lysines in histone code reading[J].Angew Chem Int Ed Engl,2013,52(52):14055-14059.
    • Related Articles

  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]CHEN Yating, WU Yue, DENG Zixian, ZHANG Yunqing, WU Shixun, SHEN Bingzheng. Research progress of microneedle in promoting wound healing[J]. Journal of China Pharmaceutical University, 2024, 55(4): 557-564. DOI: 10.11665/j.issn.1000-5048.2023082303
    [3]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [4]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [5]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [6]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [7]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [8]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [9]WU Qu, HUO Meirong, ZHOU Jianping. Advances on novel drug delivery system[J]. Journal of China Pharmaceutical University, 2013, 44(2): 97-104. DOI: 10.11665/j.issn.1000-5048.20130201
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

  • Cited by

    Periodical cited type(5)

    1. 刘梦婷，孙国祥. 格列齐特缓释片的剂量倾泻研究. 中国医药工业杂志. 2024(04): 565-570 .
    2. 周培培，孙春艳，侯晓虹. 雷诺嗪缓释片剂量倾泻方法学建立与验证. 沈阳药科大学学报. 2024(12): 1627-1633 .
    3. 刘新颖，许向阳，曾令高，毛文星，郑冬梅，高梓真. 盐酸羟考酮缓释片体外释药特性研究. 中国药业. 2023(16): 52-56 .
    4. 苗国力，郭洪涛，刘文玲，崔芹芹. 盐酸文拉法辛缓释胶囊的制备及释放度研究. 山东化工. 2023(17): 48-53 .
    5. 徐晓宏，陶铭，李飞，魏群，龚青. 缓控释微丸胶囊仿制药处方工艺研究的审评考虑. 现代药物与临床. 2023(12): 3139-3144 .

    Other cited types(0)

Catalog

    Get Citation
    XML
    Article views (2604) PDF downloads (4686) Cited by(5)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：285113

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return